help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on July 25, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-0527
A more recent version of this article appeared on November 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
91/11/4295    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boelaert, K
Right arrow Articles by Franklyn, J A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boelaert, K
Right arrow Articles by Franklyn, J A

Submitted on March 9, 2006
Accepted on July 18, 2006

Serum TSH Concentration as a Novel Predictor of Malignancy in Thyroid Nodules Investigated by Fine Needle Aspiration

K Boelaert, J Horacek, R L Holder, J C Watkinson, M C Sheppard, and J A Franklyn*

Division of Medical Sciences, IBR Building 2nd floor, The Medical School, University of Birmingham, Birmingham, B15 2TT; Department of Medicine, Charles University (Prague), Faculty of Medicine and University Hospital, Hradec Kralove, Czech Republic; Head of Statistics, Department of Primary Care and General Practice, University of Birmingham, Birmingham, B15 2TT

* To whom correspondence should be addressed. E-mail: j.a.franklyn{at}bham.ac.uk.

Context: Thyroid nodules and goiter are common and fine needle aspiration biopsy (FNAB) is the first investigation of choice in distinguishing benign from malignant disease.

Objective: To assess if simple clinical and biochemical parameters can predict the likelihood of thyroid malignancy in subjects undergoing FNAB.

Design: Prospective cohort.

Setting: Single Secondary/Tertiary Care Clinic.

Participants: 1500 consecutive patients without overt thyroid dysfunction (1304 females and 196 males, mean age 47.8 yr) presenting with palpable thyroid enlargement between 1984 and 2002 were evaluated by FNAB of the thyroid.

Intervention(s): None

Main Outcome Measures: Goiter type was assessed clinically and classified as diffuse in 183, multinodular in 456 or solitary nodule in 861 cases. Serum TSH concentration at presentation was measured in a sensitive assay in patients presenting after 1988 (n = 1183). The final cytological or histological diagnosis was determined after surgery (n = 553) or a minimum 2 yr clinical follow-up period (mean 9.5 yr, range 2-18 yr).

Results: The overall sensitivity and specificity of FNAB in predicting malignancy were 88% and 84% respectively. The risk of diagnosis of malignancy rose in parallel with the serum TSH at presentation, with significant increases evident in patients with serum TSH>0.9mU/l compared with those with lower TSH. Binary logistic regression analysis revealed significantly increased adjusted odds ratios (AOR) for the diagnosis of malignancy in subjects with serum TSH 1.0-1.7mU/l compared with TSH<0.4mU/l (AOR 2.72, 95%CI 1.02-7.27, P = 0.046), with further increases evident in those with TSH 1.8-5.5mU/l (AOR 3.88, 95%CI 1.48-10.19, P = 0.006, compared with TSH<0.4mU/l) and >5.5mU/l (AOR 11.18, 95%CI 3.23-8.63, P < 0.001, compared with TSH<0.4mU/l). Males (AOR 1.8, 95%CI 1.04-3.1, P = 0.04), younger patients (AOR 1.1, 95%CI 1.01-1.15, P = 0.025) and those with clinically solitary nodules (AOR 2.53, 95%CI 1.5-4.28, P = 0.001) were also at increased risk. Based on these findings, a formula to predict the risk of the diagnosis of thyroid malignancy in individual patients, taking into account their gender, age, goiter type determined clinically and serum TSH was calculated.

Conclusions: The risk of malignancy in a thyroid nodule increases with serum TSH concentrations within the normal range. In addition to patient's gender, age and goiter type, the serum TSH concentration at presentation is an independent predictor of the presence of thyroid malignancy. We propose that these simple clinical and biochemical factors can serve as an adjunct to FNAB in predicting risk of malignancy.


Key words: Serum TSH • fine needle aspiration biopsy • thyroid malignancy




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
M. R. Haymart, D. J. Repplinger, G. E. Leverson, D. F. Elson, R. S. Sippel, J. C. Jaume, and H. Chen
Higher Serum Thyroid Stimulating Hormone Level in Thyroid Nodule Patients Is Associated with Greater Risks of Differentiated Thyroid Cancer and Advanced Tumor Stage
J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 809 - 814.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
E. C. Ridgway, Y. Tomer, and S. M. McLachlan
Update in Thyroidology
J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3755 - 3761.
[Abstract] [Full Text] [PDF]


Home page
Arch Intern MedHome page
M. D. Gammage, J. V. Parle, R. L. Holder, L. M. Roberts, F. D. R. Hobbs, S. Wilson, M. C. Sheppard, and J. A. Franklyn
Association Between Serum Free Thyroxine Concentration and Atrial Fibrillation
Arch Intern Med, May 14, 2007; 167(9): 928 - 934.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
D. S. Ross
Predicting thyroid malignancy.
J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4253 - 4255.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society